In recent years, immune checkpoint inhibitors (ICIs), including anti-programmed cell death -1/programmed cell death ligand-1 (PD-1/PD-L1) and anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) agents, have revolutionized the management of cancer (8–10). This evidence concerns the gene PDCD1 and cancer.